Holen Sie sich die Stockscreener-App
21.52
1.89%
0.40
Handel nachbörslich:
21.52
Seaport Therapeutics Inc Aktie (SPTX) Neueste Nachrichten
Seaport Therapeutics (NASDAQ:SPTX) Stock Lifted to "Strong-Buy" by Raymond James Financial - MarketBeat
Raymond James initiates Seaport Therapeutics stock coverage with strong buy on depression drug potential - Investing.com South Africa
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap UpHere's Why - MarketBeat
Raymond James Initiates Seaport Therapeutics at Strong Buy - marketscreener.com
Seaport Therapeutics, Inc. (SPTX) stock price, news, quote and history - Yahoo Finance UK
SPTX: Pivotal phase II trials for novel neuropsychiatric drugs advance, backed by robust funding - TradingView
Seaport Therapeutics at TD Cowen summit: pipeline gains momentum By Investing.com - Investing.com Canada
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to S&P Global BMI Index - marketscreener.com
Seaport Therapeutics, Inc.(NasdaqGS:SPTX) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Seaport Therapeutics to Participate in September Investor Conferences - Business Wire
The Manufacturers Life Insurance Company Acquires New Stake in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Analysts Conflicted on These NA Names: SailPoint, Inc. (SAIL) and Seaport Therapeutics, Inc. (SPTX) - theglobeandmail.com
Analysts Offer Insights on NA Companies: Seaport Therapeutics, Inc. (SPTX), Navan, Inc. Class A (NAVN) and International Business Machines (IBM) - The Globe and Mail
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 4.6%Should You Buy? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX) - MarketBeat
symbol__ Stock Quote Price and Forecast - cnn.com
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - biospace.com
Seaport Therapeutics at citigroup’s biopharma back to school summit 2026: platform push - Investing.com Canada
Seaport Therapeutics reports positive phase 1 trial results - investing.com
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Seaport Therapeutics reports positive phase 1 trial results By Investing.com - Investing.com Canada
PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo - TradingView
RCSPureTech Health PLCPRTC's SPTX: New Positive Phase 1 GlyphAllo Data - TradingView
Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial - marketscreener.com
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Business Wire
Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.ca
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - BioSpace
Trv Gp Vi LLC Acquires New Shares in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 5.2%Here's Why - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week HighHere's Why - MarketBeat
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - 24/7 Wall St.
Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Selvaraju Reiterates Buy on Seaport, Citing Differentiated Neuropsychiatry Pipeline and Unchanged $50 Price Target - TipRanks
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake - Stock Titan
Stifel Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Top Seaport Therapeutics (SPTX) Competitors 2026 - MarketBeat
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation - Seeking Alpha
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):